The company will use the funding to advance clinical trials for Tune-401, the epigenetic silencing drug for treating chronic ...

Her previous roles at Juno Therapeutics, Celgene, and Lyell Immunopharma, and her current position as head of research at Tune Therapeutics, underscore her commitment to pioneering cancer treatments.

She has held research leadership roles at organizations including Juno Therapeutics, Celgene, and Lyell Immunopharma and is currently the head of research at Tune Therapeutics. She brings strong ...

She has held research leadership roles at organizations including Juno Therapeutics, Celgene, and Lyell Immunopharma and is currently the head of research at Tune Therapeutics. She brings strong ...